| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Purpose: To evaluate the results of intravitreal use of Pegaptanib in patients with exudative age-related macular degeneration (AMD). Methods: Our study includes 77 patients with exudative AMD, who received 9 injections of Pegaptanib 0.3mg with 6-weeks intervals between them. So the primary treatment lasted one year. During and after the treatment these patients underwent fluorescent angiography (FAG), optical coherent tomography (OCT), fundus photography and best corrected visual acuity (BCVA) examination. According to the results of these examinations a decision about further treatment, whether it was necessary, was taken. Results: By the end of our 2-year study 38 patients after therapy with Pegaptanib had complete obliteration of the choroidal neovascularization (CNV), 19 patients were switched to Ranibizumab, one patient underwent photodynamic therapy with Visudyne, 14 patients had severe progression of AMD, when there was no sense in further treatment, 2 patients dropped out the study because of cerebral insult, 3 patients refused of any further treatment, in spite of persisting exudative activity of the CNV after the primary treatment. Conclusion: Intravitreal application of Pegaptanib is a relatively effective treatment option of exudative AMD as BCVA was stabilized or improved in 55,8% of patients, macular edema decreased in 67,5% of patients and neovascular membrane was obliterated in 49,35% of patients. (en)
- Cel': Ocenit' rezul'taty intravitreal'nogo primeněnija Pegaptaniba u pacijentov s ekssudativnoj formoj vozrastnoj makuljarnoj děgeněracii (VMD). Matěrial i metody: Issledujemuju gruppu sostavili 77 pacijentov s ekssudativnoj formoj VMD, kotorye polučili 9 intravitreal'nych in'jekcij 0,3 mg Pegaptaniba s šestiněděl'nym intěrvalom meždu nimi. Takim obrazom, pervonačal'naja těrapija dlilas' 1 god. V processe i posle lečenija pacijentam provodilis' fljuorescentnaja angiografija (FAG), optičeskaja kogerentnaja tomografija (OKT), fotoregistracija glaznogo dna i izmerenija ostroty zrenija s maksimal'noj korrekcijej. Po ich rezul'tatam prinimalos' rešenije o dal'nějšej lečebnoj taktike v těch slučajach, gdě eto bylo něobchodimo.Rezul'taty: K koncu našego dvuchletněgo issledovanija polnaja oblitěracija chorioidal'noj něovaskuljarizacii (ChNV) pod vozdějstvijem Pegaptaniba nabljudalas' u 38 pacijentov; 19 pacijentov prišlos' perevesti na intravitreal'nye in'jekcii Ranibizumaba; odnomu pacijentu byla naznačena fotodinamičeskaja těrapija s Vizudinom; u 14 bol'nych patologičeskij process progressiroval do stadii, kogda kakaja-libo dal'nějšaja těrapija bessil'na; 2 pacijentki vybyli po sostojaniju zdorov'ja (krovoizlijanije v mozg); 3 pacijenta posle pervogo kursa in'jekcij Pegaptaniba otkazalis' ot prodolženija lečenija, něsmotrja na sochranivšujusja ekssudativnuju aktivnost' ChNV membrany. Vyvody: Intravitreal'noje primeněnije Pegaptaniba javljaetsja otnositěl'no effektivnoj vozmožnost'ju lečenija ekssudativnoj formy VMD, tak kak stabilizacija i ulučšenije ostroty zrenija nastupili v 55,8% slučajev, umen'šenije makuljarnogo otjoka otmečalos' v 67,5% slučajev, oblitěracija něovaskuljarnoj membrany diagnostirovalas' v 49,35% slučajev.
|
| Title
| - Clinical outcomes of the treatment of exudative age-related macular degeneration with Pegaptanib (en)
- Kliničeskije rezul'taty lečenija ekssudativnoj formy vozrastnoj makuljarnoj děgeněracii Pegaptanibom
|
| skos:prefLabel
| - Clinical outcomes of the treatment of exudative age-related macular degeneration with Pegaptanib (en)
- Kliničeskije rezul'taty lečenija ekssudativnoj formy vozrastnoj makuljarnoj děgeněracii Pegaptanibom
|
| skos:notation
| - RIV/00179906:_____/13:10190979!RIV14-MZ0-00179906
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00179906:_____/13:10190979
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - treatment; Pegaptanib; exudative; choroidal neovascularization; age-related macular degeneration (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Burova, Mariya
- Jirásková, Naďa
- Kalfeřtová, Marie
- Rozsíval, Pavel
- Studnička, Jan
|
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)